Meet our 
leadership team

Get to know our proposed Board of Directors, Executive Leadership Team and ownership structure.

Our proposed nine-member Board of Directors and 10-member Executive Leadership Team have broad and global management experience, comprehensive biotech expertise and in-depth knowledge of our business.  

The proposed Board of Directors is to be elected at an Extraordinary General Meeting during Q1 2024. Learn more about our proposed candidates for the Board below.  

Proposed candidates to the Board of Directors

Executive Leadership Team

Our ownership structure

Management in Novonesis is headed by a Board of Directors and Executive Leadership Team. Novo Holdings A/S is the holding company for companies in the Novo Group, with an ownership stake in Novozymes A/S. Our leadership and governance structure promotes transparent and sustainable corporate value creation.

Novozymes’ stock consists of two types: A and B shares. Both shares have a nominal value of DKK 2 per share, but an A share carries 10 times as many votes as a B share.

Novozymes had approximately 100.000 shareholders just after completion of the merger. At that time Novo Holdings A/S held 23,87% of the total common stock in Novozymes and controlled 62.55% of the votes.

The Novo Nordisk Foundation wishes to be an “Engaged Owner” in relation to Novozymes and apply engaged ownership objectives and principles which among other things are described in ‘Objectives & Principles for engaged ownership in relation to Novo Nordisk A/S and Novozymes A/S’, cf. www.novonordiskfonden.com. The Novo Nordisk Foundation supports Novozymes in achieving its vision, ensuring competitive financial results and adhering to the Charter for Companies in the Novo Group. All strategic and operational matters are solely decided by the Board and the Executive Management of Novozymes.